Article Details

AstraZeneca and MSD's Lynparza approved in the EU for prostate cancer

Retrieved on: 2022-12-21 07:53:46

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca and MSD's Lynparza approved in the EU for prostate cancer. View article details on hiswai:

Excerpt

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Many patients with metastatic castration-resistant prostate ...

Article found on: www.directorstalkinterviews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up